Association of CCL21+ CAFs with B-cell recruitment and TLS maturation in penile squamous cell carcinoma.
Saved in:
| Title: | Association of CCL21+ CAFs with B-cell recruitment and TLS maturation in penile squamous cell carcinoma. |
|---|---|
| Authors: | Li X; Department of Medical Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, People's Republic of China., Chen D; Department of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.; Department of Urology, First Affiliated Hospital of Southern, University of Science and Technology, Shenzhen, 518107, Guangdong, People's Republic of China.; Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital, Shenzhen, 518107, People's Republic of China., Guo Y; Department of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.; Department of Urology, First Affiliated Hospital of Southern, University of Science and Technology, Shenzhen, 518107, Guangdong, People's Republic of China.; Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital, Shenzhen, 518107, People's Republic of China., Huang G; Department of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.; Department of Urology, First Affiliated Hospital of Southern, University of Science and Technology, Shenzhen, 518107, Guangdong, People's Republic of China.; Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital, Shenzhen, 518107, People's Republic of China., Cai Z; Department of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.; Department of Urology, First Affiliated Hospital of Southern, University of Science and Technology, Shenzhen, 518107, Guangdong, People's Republic of China.; Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital, Shenzhen, 518107, People's Republic of China., Xue T; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China., Chen Z; Department of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.; Department of Urology, First Affiliated Hospital of Southern, University of Science and Technology, Shenzhen, 518107, Guangdong, People's Republic of China.; Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital, Shenzhen, 518107, People's Republic of China., Han H; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. hanhui@sysucc.org.cn.; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. hanhui@sysucc.org.cn.; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 10060, Guangdong, People's Republic of China. hanhui@sysucc.org.cn., Li Z; Department of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China. lizaishang2017@163.com.; Department of Urology, First Affiliated Hospital of Southern, University of Science and Technology, Shenzhen, 518107, Guangdong, People's Republic of China. lizaishang2017@163.com.; Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital, Shenzhen, 518107, People's Republic of China. lizaishang2017@163.com. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Mar 17; Vol. 75 (4). Date of Electronic Publication: 2026 Mar 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
